“…[1][2][3][4][5][6][7] Dupilumab, a monoclonal antibody for the treatment of AD, targets the IL-4 receptor subunit a, shared by IL-4 and IL-13 receptors. 8 Dupilumab effectiveness in AA was evaluated in a phase IIa clinical trial including 40 subjects receiving weekly subcutaneous dupilumab 300 mg, and 20 subjects receiving placebo. 9 After 48 weeks of treatment, the percentage of patients achieving the improvement in Severity of Alopecia Tool (SALT) score of 30% (SALT30)/SALT50/SALT75 was 32.5%, 22.5% and 15% respectively.…”